Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2327-2333

  Freedman, Andrew N ^a,b,c,d   Yu, Binbing ^a,b,c,d   Gail, Mitchell H ^a,b,c,d   Costantino, Joseph P ^a,b,c,d   Graubard, Barry I ^a,b,c,d   Vogel, Victor G ^a,b,c,d   Anderson, Garnet L ^a,b,c,d   McCaskill Stevens, Worta ^a,b,c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

AGE; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CATARACT; CAUCASIAN; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COLLES FRACTURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HIP FRACTURE; HISPANIC; HUMAN; IN SITU BREAST CANCER; INVASIVE BREAST CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NEGRO; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SPINE FRACTURE; STROKE; UTERUS;

AGED; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; ESTROGEN ANTAGONISTS; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; RALOXIFENE; TAMOXIFEN;

EID: 79959199141     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.0258     Document Type: Article

References (27)

1. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998 (Pubitemid 28439961)
2. Cuzick J, Forbes J, Edwards R, et al: First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-824, 2002 (Pubitemid 35257944)
3. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998 (Pubitemid 28321321)
4. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women - Italian Tamoxifen Prevention Study. Lancet 352:93-97, 1998 (Pubitemid 28321320)
5. Gail MH, Costantino JP, Bryant J, et al: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999.
6. Cranney A, Guyatt G, Griffith L, et al: Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578, 2002
7. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial - Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645, 1999 (Pubitemid 29384151)
8. Barrett-Connor E, Mosca L, Collins P, et al: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137, 2006 (Pubitemid 44050394)
9. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295:2727-2741, 2006
10. US Food and Drug Administration: Raloxifene hydrochloride, approved September 13, 2007. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129243. htm
11. National Comprehensive Cancer Network (NCCN): NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines, February 3, 2009. http://www.nccn.org/about/news/newsinfo.asp?NewsID=200
12. US Preventive Services Task Force (USPSTF): Chemoprevention of Breast Cancer: Summary of recommendations/supporting documents, July 2002. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrpv.htm
13. Visvanathan K, Chlebowski RT, Hurley P, et al: American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258, 2009
14. Nelson HD, Fu R, Griffin JC, et al: Systematic review: Comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 151:703-715, 2009
15. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002 (Pubitemid 34761611)
16. Centers for Disease Control and Prevention: National Center for Health Statistics: National Health Interview Survey. http://www.cdc.gov/nchs/nhis.htm
17. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989
18. Costantino JP, Gail MH, Pee D, et al: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548, 1999 (Pubitemid 29457958)
19. Anderson SJ, Ahnn S, Duff K: NSABP Breast Cancer Prevention Trial risk assessment program, Version 2. University of Pittsburgh, Department of Biostatistics, Pittsburgh, PA, August 14, 1992
20. Gail MH, Costantino JP, Pee D, et al: Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99:1782-1792, 2007 (Pubitemid 351767204)
21. Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004 (Pubitemid 38489892)
22. Design of the Women's Health Initiative clinical trial and observational study: The Women's Health Initiative Study Group. Control Clin Trials 19:61-109, 1998
23. Vogel VG, Costantino JP, Wickerham LD, et al: Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prev Res (Phila) 3:696-706, 2010
24. National Cancer Institute: Breast Cancer Risk Assessment Tool (BCRAT). http://www.cancer.gov/gov/bcrisktool/
25. Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A: Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: A systematic review. Int J Cancer 15; 121(2):225-231, 2007
26. Cuzick J, Forbes JF, Sestak I, et al: Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 21; 99(4):272-282, 2007 (Pubitemid 47073490)
27. Powles TJ, Ashley S, Tidy A, et al: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283-290, 2007 (Pubitemid 47073491)